Journal
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Volume 70, Issue 2, Pages 627-632Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejpb.2008.05.007
Keywords
Poly(n-butylcyano-acrylate) (PBCA) nanoparticles; Blood-brain barrier; Drug delivery
Categories
Ask authors/readers for more resources
This study aimed to explore and extend the application potential of poly(n-butylcyano-acrylate) (PBCA) nanoparticles to cross the blood-brain barrier (BBB) and to deliver their content into the central nervous system. PBCA particles were prepared by a new and efficient mini-emulsion method with excellent yield and reproducibility. These nanoparticles were loaded with 1.5% (w/v) fluorescein-isothio-cyanate-dextran (FITC-dextran), 1.5% rhodamine-123 or 7.3% doxorubicin. Particles were characterized by dynamic light scattering determining particle size, polydispersity index and zeta-potential. They were coated with 10% w/v polysorbate 80 and administered to rats. Cryosections of the brain were prepared and time-dependent distribution Of fluorescence was studied. After the administration of polysorbate 80-coated particles by carotic injection, fluorescence could first be detected in capillary lumina with a progressive shift to capillary endothelial cells at 30 min and a rather evenly spread distribution across the brain tissue at 60 min after administration. 60 min after administration into the tail vein, fluorescent particles could be assigned to endothelial cells, whereas after 2 h a rather evenly spread distribution across the brain tissue was seen. These observations indicate that surface-coated PBCA nanoparticles are able to cross the blood-brain barrier and to serve as a drug-delivery, system to the central nervous system. (C) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available